New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 15, 2014
06:30 EDTP, VIVHY, SNEDOJ investigating music publishing, possible price coordination, WSJ reports
The DOJ has requested documents from Sony's (SNE) Sony/ATV Music Publishing and Vivendi's Universal Music Publishing, along with the American Society of Composers, Authors and Publishers and Broadcast Music, and is seeking documents related to a wide range of licensing issues, the Wall Street Journal reports. Under investigation is possible pricing coordination among music publishing companies. Reference Link
News For SNE;VIVHY;P From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
September 23, 2015
05:20 EDTVIVHYVivendi upgraded to Hold from Underperform at Jefferies
Subscribe for More Information
September 22, 2015
12:54 EDTSNEGoPro CEO says market share has grown since Sony entered market
Subscribe for More Information
12:53 EDTSNEGoPro CEO says competitors like Sony have helped grow total reach
Subscribe for More Information
08:09 EDTPPandora royalty risk reduced, says JMP Securities
Subscribe for More Information
September 21, 2015
16:53 EDTSNE, POn The Fly: Top stock stories for Monday
Stocks on Wall Street began the session in positive territory and remained there for most of the morning. The Nasdaq was the first index to show signs of weakness after Hillary Clinton pledged to address the high cost of specialty drugs, sinking multiple biotech stocks. The averages later recovered from their afternoon lows, with both the Dow and S&P posting gains and the Nasdaq narrowly finishing in the green after Monday's drug pricing debate. ECONOMIC EVENTS: In the U.S., existing home sales fell 4.8% to a 5.31M rate in August, versus expectations for them to be down 1.6% to a rate of 5.5M. Over the weekend, three Federal Reserve officials, namely San Francisco Fed President John Williams, St. Louis Fed President James Bullard and Richmond Fed President Jeffrey Lacker, all argued that an interest-rate increase is still warranted this year. COMPANY NEWS: Biotech stocks declined after privately-held Turing Pharmaceuticals made headlines by enacting a 5,000% price increase on its treatment for toxoplasmosis, reigniting a debate around drug prices that previously embroiled costly Hepatitis C drugs including AbbVie's (ABBV) Viekira Pak and Gilead's (GILD) Sovaldi and Harvoni. Presidential candidate Hillary Clinton sent the debate to center stage by criticizing the "outrageous" prices of specialty drugs and promising to lay out a plan tomorrow to tackle "price gouging" in the specialty drug market. The NASDAQ Biotechnology index fell roughly 4.4% following the attention paid to Turing's drug and Clinton's response... Shares of Volkswagen (VLKAY) trading in New York dropped 17.1% to $30.10 after the EPA and California Air Resources Board detected manipulations that violate U.S. environmental standards while testing certain Volkswagen diesel cars. The EPA said Volkswagen may face civil penalties of $37,500 for each vehicle not in compliance with federal clean air rules, which could total as much as $18B, according to Reuters... Apple (AAPL), which has previously been reported to be working on an electric car via its "Project Titan," is speeding up those efforts and setting 2019 as a target to ship its first vehicle, according to The Wall Street Journal. Shares of Tesla Motors (TSLA) were volatile following the Journal's report, but closed the day up 1.37% at $264.20. MAJOR MOVERS: Among the notable gainers was Atmel (ATML), which surged 12.65%, to $8.19 after agreeing to be acquired by German chipmaker Dialog Semiconductor in a deal valued at roughly $4.6B. Also higher was Starwood Waypoint (SWAY), which gained $2.89, or 12.70%, to $25.64 after announcing a stock-for-stock merger agreement with Colony American Homes. Additionally, Pandora (P) rose 8.17% to $21.31 after receiving an interim opinion from the Register of Copyrights regarding the company's agreements with Merlin and Naxos. Among the noteworthy losers was GoPro (GPRO), which fell $2.88, or 8.19%, to $32.27 after Barron's contended that the company's stock could plunge another 30% to $25 as Apple, Sony (SNE), and others pressure the company's "one-hit wonder" products. Also lower was Mallinckrodt (MNK), which lost $8.23, or 10.02%, to $73.87 after ANI Pharma (ANIP) announced plans to acquire two new drug applications from Merck (MRK) that could compete with Acthar, Mallinckrodt's largest product. Separately, D.R. Horton (DHI) dipped 2.91% after the August U.S. existing home sales report showed a 4.8% drop for the month. Note also that Lennar (LEN) slipped 0.27% after its quarterly earnings report beat analyst estimates. INDEXES: The Dow rose 125.61, or 0.77%, to 16,510.19, the Nasdaq added 1.73, or 0.04%, to 4,828.96, and the S&P 500 gained 8.94, or 0.46%, to 1,966.97.
14:18 EDTPCRB comments actually cautionary for Pandora, says FBR Capital
The initial positive reaction in Pandora shares following a procedural decision in its CRB rate fight seems misplaced, according to FBR, which argues that language in the decision is actually cautionary for Pandora. The firm, which said that the ruling includes favorable comments for SoundExchange, keeps an Underperform rating on Pandora.
12:25 EDTPPandora interim ruling win a positive sign, says Piper Jaffray
Subscribe for More Information
12:19 EDTPPandora says 'pleased' with opinion from Register of Copyrights
Subscribe for More Information
11:24 EDTPPandora January puts active on Copyright Royalty Board decision
Subscribe for More Information
11:17 EDTPPandora 'pleased' copyright office affirmed Merlin pact as benchmark
In statement to Reuters, Pandora said it is "pleased that the copyright office affirmed the admissibility of Pandora's agreement with Merilin as a valid benchmark in the copyright royalty board proceedings," the news service reported.
10:51 EDTPOptions with increasing implied volatility
Subscribe for More Information
10:49 EDTSNEGoPro falls after Barron's predicts 'dramatic' drop in share price
GoPro (GPRO) shares fell in morning trading after an article from Barron's argued that the company's share price may drop to as low as $25. WHAT'S NEW: Alexander Eule argued in a Barron's article that GoPro's stock price may see a "dramatic" slip of as much as 30% to $25 due to significant competitive pressure from Apple (AAPL), Sony (SNE) and others. Eule noted that the company's shares have crashed to a recent $35 after peaking at $98 in October 2014 and even called the mostly bullish analyst views on the camera maker's stock "wishful thinking." Additionally, Eule called the company's cameras a "one-product wonder" and compares them to BlackBerry (BBRY) smartphones and Palm digital organizers, which previously dominated their respective markets. The article adds that there is risk in being overly bearish on the company, since the "impressive" brand might become an acquisition target. WHAT'S NOTABLE: Last Wednesday, Citi analyst Jeremy David said that GoPro chief financial officer Jack Lazar confirmed at the bank's Global Tech Conference the week before that the Hero4 Session camera has been off to a slow start since its launch on July 12. David said that the recent selloff in the company's shares has been motivated by investor concerns about the Session. At the time, Citi cut its third quarter fiscal 2015 estimate for the company to $425M from $438M and fourth quarter estimate to $560M from $737M, $148M below consensus estimate at the time of $708M. David also said he was reducing estimates for the second half of fiscal 2015 and first quarter of fiscal 2016 as a result of downside from the Hero4 Session, but left estimates after 1Q16 unchanged, saying the long-term fundamentals of the company are "intact." The analyst added that his firm was "humbled" by the recent move in share price and acknowledged that GoPro is the "quintessential product cycle stock," though he said he remains bullish on the long-term prospects of the camera maker and reiterated a $90 price target. David argued that GoPro missing Q3 estimates and guiding below the consensus for Q4 is largely priced in. Separately, The Wall Street Journal said on September 13 that shares of GoPro were starting to look like a bargain after dropping 50% in a month. The company had a difficult time selling its Hero4 Session camera in July in the face of competition from older GoPro models, the publication added. PRICE ACTION: In morning trading, GoPro shares are down 5.15% to $33.34. OTHERS TO WATCH: Ambarella (AMBA), which supplies chips to GoPro, is down 3.7% to $68.81.
10:43 EDTPPandora well off highs, shares still up 5% to $20.64
Subscribe for More Information
10:25 EDTPPandora trading resumes, shares up 13% to $22.26
10:18 EDTPPandora halted second time for volatility after jumping 8% to $21.31
Subscribe for More Information
10:17 EDTPPandora trading resumes, shares now up 8% to $21.30
10:16 EDTPPandora jumps as investors await Copyright Royalty Board decision
Subscribe for More Information
10:13 EDTPPandora trading halted for volatility after jumping $1.28 to $20.98
September 20, 2015
19:48 EDTSNE'Maze Runner' sequel outpaces 'Black Mass'
Young-adult science fiction film "Maze Runner: The Scorch Trials" raced ahead of Johnny Depp-led crime biopic "Black Mass" in their respective weekend debuts. WEEKEND LEADER: Falling somewhat short of estimated sales in the range of $34M-$36M, Fox's (FOX, FOXA) "Maze Runner: The Scorch Trials" grossed $30.3M domestically for the weekend of September 20. The sci-fi action thriller's $61M budget nearly doubles that of the first "Maze Runner" film, building on a trend of dystopic young-adult films popularized by Lionsgate's (LGF) "The Hunger Games" and "Divergent." BOX OFFICE RUNNERS-UP: "Black Mass" from Time Warner (TWX) subsidiary Warner Bros. took in $23.4M for its domestic open. The Boston-based crime film garnered acclaim from critics and audiences alike, with particular praise given to Johnny Depp in the role of mobster Whitey Bulger. Meanwhile, Comcast (CMCSA, CMCSK) subsidiary Universal's horror thriller "The Visit" earned $11.4M in its second week in theaters, while Sony (SNE) thriller "The Perfect Guy" fell to fourth place with $9.7M. Rounding out this weekend's Top 5, Universal's disaster film "Everest" grossed $7.6M despite opening in just 545 theaters ahead of its wider release.
12:49 EDTSNEGoPro shares could fall another 30% to $25, Barron's says
Subscribe for More Information
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use